GlassScriptPhysician profile
Suzanne Southerland
NPI 1518985134
$2,026.06
in general payments reported to CMS, 2019-2025
20 companies · $445 in 2025
The $445 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $279 · 2021: $435 · 2022: $148 · 2023: $87.55 · 2024: $197 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $708.28 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Glaxosmithkline, LLC. | $317.53 | 2021-2025 | Penmenvy, Bexsero, Rotarix |
| Neos Therapeutics, LP | $147.50 | 2019-2025 | Cotempla Xr-Odt |
| Collegium Pharmaceutical, INC. | $129.50 | 2025 | Jornay Pm |
| Kaleo, INC. | $118.67 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $109.34 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $91.50 | 2024-2025 | |
| Adlon Therapeutics L.P. | $69.21 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.41 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $48.34 | 2023-2024 | Flumist Quadrivalent |
| Pfizer INC. | $43.99 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $33.56 | 2022-2025 | Vaxneuvance, Enflonsia, Gardasil 9 |
| Cranial Technologies, INC | $32.30 | 2019-2021 | |
| Sanofi Pasteur INC. | $23.23 | 2022 | |
| Verrica Pharmaceuticals INC. | $22.84 | 2024 | Ycanth |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $20.52 | 2021 | |
| Phadia US INC. | $16.39 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.16 | 2025 | Qelbree |
| Rhodes Pharmaceuticals L.P. | $14.83 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.96 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Southerland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.